Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept weight-banded versus weight-based dosing pharmacokinetic study in pulmonary arterial hypertension
NL-OMON60553Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sotatercept in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Merck & Co. Primary endpoints: Steady-state average serum concentrations of sotatercept (Cavg), Number of participants who experience one or more adverse events and 1 more. Started Dec 2024; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON60553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60553.